Billion-Dollar Molecules: Voxelotor, A $5.4 Billion Reversible Covalent Aldehyde

Abstract. Voxelotor, a gram-daily reversible covalent aldehyde drug, is an approved first-in-class oral drug that prevents the hemoglobin polymerization that drives sickle cell disease. It was one of several agents in clinical trials acquired from Global Blood Therapeutics by Pfizer as part of an over $5 billion buyout. In this article, we dive into:

  • the mechanism of action of the first-in-class drug
  • the clinical context of the acquired portfolio
  • the drug discovery story of this new drug class

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.


Join Subscribers from

…and hundreds more!